conferenceseries.com

Nicolas Céline et.al., J Clin Trials 2018, Volume 8 DOI: 10.4172/2167-0870-C1-023

5th World Congress on

ADVANCED CLINICAL TRIALS AND CLINICAL RESEARCH

May 14-15, 2018 Singapore

Evaluation of the tolerance of a new Metronidazole-based oral suspension in puppies

Nicolas Céline and Ayadi N

Virbac, France

The objective of this study was to evaluate the tolerance of a new metronidazole-based oral suspension (Eradia[™], Virbac) following daily administration to beagle puppies (aound 12 weeks old). Three groups of 8 dogs received either one (1X), two (2X) or three (3X) times the recommended therapeutic dose (25 mg/kg BW, twice a day) for three times the duration of treatment (i.e. 15 consecutive days). Another group received five (5X) times the therapeutic dose for the intended duration of treatment (i.e. 5 consecutive days) and another group was used as control (placebo). A clinical examination and body weight recording were performed on pre-test and on days 1, 6, 11 and 16. The amount of food and water consumed was recorded daily. Blood and urine were collected on pre-test and on day 16 for hematology, blood biochemistry (including C-reactive protein levels) and urinary investigations. On completion, the animals were sacrificed and a full macroscopic and microscopic post-mortem examination was performed. No unscheduled deaths occurred and no clinical signs of toxicological importance were observed at any dose-level. No drug-related observations were recorded and body weight, food and water consumption were unaffected. At laboratory investigations (hematology, blood biochemistry, C-reactive protein levels and urinalysis), no drug-related changes were noted. Finally, no organ weight changes and no macroscopic or microscopic findings related to the treatment were observed. Therefore, Eradia[™] was well tolerated by puppies up to 3X the dose for 15 days or at 5X the dose for 5 days.

Biography

Nicolas Céline has graduated in Veterinary Medicine and obtained her PhD from the University of Nantes, France. She has then worked as a Post-doctoral Fellow and Research Assistant at the University of Bristol, UK for 5 years and at the University of Nice, France for 2 years. She has published a dozen articles in reputed journals and joined Virbac medical department in 2016.

celine.nicolas@virbac.com

Notes: